FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321189516> ?p ?o ?g. }

• W4321189516 endingPage "100035" @default.
• W4321189516 startingPage "100035" @default.
• W4321189516 abstract "Real-world data on use of PCSK9 inhibitors (PCSK9-Is), with or without statins and/or ezetimibe, and associated outcomes, can inform more effective prescribing. The objective was to evaluate clinical effectiveness and safety of PCSK9-Is within the Veterans Health Administration (VHA). In this retrospective cohort study, we included Veterans who had at least one outpatient prescription for alirocumab and/or evolocumab filled within VHA between August 21, 2015, and September 30, 2020. Analyses included 4 mutually exclusive subgroups: PCSK9-I alone, PCSK9-I+statin, PCSK9-I+ezetimibe, and PCSK9-I+statin+ezetimibe subgroups. Primary outcomes included medication possession ratio, persistence, and low-density lipoprotein (LDL). Among Veterans in the analytical cohort (n = 2428), 36.2% were on PCSK9-I monotherapy; 24.0% received a PCSK9-I+statin; 27.4% were on a PCSK9-I+ezetimibe; and 12.4% received triple therapy, that is, PCSK9-I+statin+ezetimibe. The mean medication possession ratio (standard deviation [SD]) for PCSK9-I monotherapy was 83.8% (13.3) compared to 84.3% (11.2) with PCSK9-I+statin therapy, 87.1% (10.1) with PCSK9-I+ezetimibe therapy, and 85.8% (11.7) with triple therapy. The percentage of patients who discontinued PCSK9-I in the monotherapy subgroup was 12.3% vs 9.5%, 6.6%, and 7.4% in the concomitant statin, ezetimibe, and triple-therapy subgroups, respectively (p = .002 among the groups). Mean LDL level was greater in the PCSK9-I monotherapy subgroup (85.6 mg/dL) compared with the concomitant statin (66.5 mg/dL), ezetimibe (65.7 mg/dL), and triple-therapy subgroups (68.1 mg/dL). Veterans showed good adherence and/or persistence with PCSK9-I regimens. On average, those receiving concomitant therapy with a statin and/or ezetimibe achieved significantly lower LDL levels." @default.
• W4321189516 created "2023-02-18" @default.
• W4321189516 creator A5012742878 @default.
• W4321189516 creator A5016027755 @default.
• W4321189516 creator A5017141384 @default.
• W4321189516 creator A5034224254 @default.
• W4321189516 creator A5039605963 @default.
• W4321189516 creator A5049997857 @default.
• W4321189516 creator A5055924995 @default.
• W4321189516 creator A5062137377 @default.
• W4321189516 creator A5065875700 @default.
• W4321189516 date "2023-06-01" @default.
• W4321189516 modified "2023-10-18" @default.
• W4321189516 title "PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration" @default.
• W4321189516 cites W1520609538 @default.
• W4321189516 cites W1556783812 @default.
• W4321189516 cites W2061326496 @default.
• W4321189516 cites W2137370054 @default.
• W4321189516 cites W2588058696 @default.
• W4321189516 cites W2596179513 @default.
• W4321189516 cites W2742316776 @default.
• W4321189516 cites W2768968665 @default.
• W4321189516 cites W2791399898 @default.
• W4321189516 cites W2800944065 @default.
• W4321189516 cites W2806550872 @default.
• W4321189516 cites W2895473490 @default.
• W4321189516 cites W2899997727 @default.
• W4321189516 cites W2904210113 @default.
• W4321189516 cites W2941101173 @default.
• W4321189516 cites W2944503309 @default.
• W4321189516 cites W2986028519 @default.
• W4321189516 cites W2987775975 @default.
• W4321189516 cites W2992678675 @default.
• W4321189516 cites W2998463961 @default.
• W4321189516 cites W3015010867 @default.
• W4321189516 cites W3017798522 @default.
• W4321189516 cites W3046033709 @default.
• W4321189516 cites W3098063240 @default.
• W4321189516 cites W3134494651 @default.
• W4321189516 cites W3159869323 @default.
• W4321189516 cites W3203433276 @default.
• W4321189516 cites W4206987057 @default.
• W4321189516 cites W4226475746 @default.
• W4321189516 cites W4309163008 @default.
• W4321189516 doi "https://doi.org/10.1016/j.ajmo.2023.100035" @default.
• W4321189516 hasPublicationYear "2023" @default.
• W4321189516 type Work @default.
• W4321189516 citedByCount "0" @default.
• W4321189516 crossrefType "journal-article" @default.
• W4321189516 hasAuthorship W4321189516A5012742878 @default.
• W4321189516 hasAuthorship W4321189516A5016027755 @default.
• W4321189516 hasAuthorship W4321189516A5017141384 @default.
• W4321189516 hasAuthorship W4321189516A5034224254 @default.
• W4321189516 hasAuthorship W4321189516A5039605963 @default.
• W4321189516 hasAuthorship W4321189516A5049997857 @default.
• W4321189516 hasAuthorship W4321189516A5055924995 @default.
• W4321189516 hasAuthorship W4321189516A5062137377 @default.
• W4321189516 hasAuthorship W4321189516A5065875700 @default.
• W4321189516 hasBestOaLocation W43211895161 @default.
• W4321189516 hasConcept C126322002 @default.
• W4321189516 hasConcept C2776839432 @default.
• W4321189516 hasConcept C2778114629 @default.
• W4321189516 hasConcept C2778163477 @default.
• W4321189516 hasConcept C2778657065 @default.
• W4321189516 hasConcept C2779384505 @default.
• W4321189516 hasConcept C2780072125 @default.
• W4321189516 hasConcept C2780745583 @default.
• W4321189516 hasConcept C2780902209 @default.
• W4321189516 hasConcept C2780948078 @default.
• W4321189516 hasConcept C43554185 @default.
• W4321189516 hasConcept C71924100 @default.
• W4321189516 hasConcept C72563966 @default.
• W4321189516 hasConceptScore W4321189516C126322002 @default.
• W4321189516 hasConceptScore W4321189516C2776839432 @default.
• W4321189516 hasConceptScore W4321189516C2778114629 @default.
• W4321189516 hasConceptScore W4321189516C2778163477 @default.
• W4321189516 hasConceptScore W4321189516C2778657065 @default.
• W4321189516 hasConceptScore W4321189516C2779384505 @default.
• W4321189516 hasConceptScore W4321189516C2780072125 @default.
• W4321189516 hasConceptScore W4321189516C2780745583 @default.
• W4321189516 hasConceptScore W4321189516C2780902209 @default.
• W4321189516 hasConceptScore W4321189516C2780948078 @default.
• W4321189516 hasConceptScore W4321189516C43554185 @default.
• W4321189516 hasConceptScore W4321189516C71924100 @default.
• W4321189516 hasConceptScore W4321189516C72563966 @default.
• W4321189516 hasLocation W43211895161 @default.
• W4321189516 hasOpenAccess W4321189516 @default.
• W4321189516 hasPrimaryLocation W43211895161 @default.
• W4321189516 hasRelatedWork W2626674165 @default.
• W4321189516 hasRelatedWork W2911702236 @default.
• W4321189516 hasRelatedWork W2922111129 @default.
• W4321189516 hasRelatedWork W2979834087 @default.
• W4321189516 hasRelatedWork W3103075301 @default.
• W4321189516 hasRelatedWork W3216652272 @default.
• W4321189516 hasRelatedWork W4245825619 @default.
• W4321189516 hasRelatedWork W4306247171 @default.
• W4321189516 hasRelatedWork W4366606415 @default.
• W4321189516 hasRelatedWork W2169633553 @default.

• next